Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 663 for “"MEK"”.

  1. The Role of MEK in Leukemogenesis

    … on the effect of inappropriate activation of MEK/ERK, a downstream Ras effector pathway, in the hematopoietic system.</p><p>Using a retroviral transduction system, we expressed a constitutively active form of MEK1 in hematopoietic stem cells (HSCs). Mice transplanted with HSCs expressing …

    duke Repository record for The Role of MEK in Leukemogenesis (opens in a new tab)

  2. Pharmacological effect of MEK inhibitors on plasmodium falciparum

    … modules comprising the MAPK and upstream MAPKKs (MEKs) and MAPKKKs (MEKKs). Surprisingly, experimental and in silico analyses have demonstrated P. falciparum does not possess any MEK homologues, even though its kinome comprises two members of the MAP kinase family. Prior to the finding that the …

    glasgow Download PDF for Pharmacological effect of MEK inhibitors on plasmodium falciparum (opens in a new tab)

  3. BPGAP1 REGULATES MP1 SCAFFOLD FUNCTION IN MEK/ERK SIGNALING

    PRECISE SPATIOTEMPORAL CONTROL OF MEK/ERK SIGNALING IS ESSENTIAL TO REGULATE CELL PROLIFERATION, DIFFERENTIATION OR SURVIVAL. MP1 (MEK PARTNER1) IS A LATE ENDOSOMAL SCAFFOLD THAT SPECIFICALLY RECRUITS ACTIVE MEK1 (MITOGEN-ACTIVATED PROTEIN KINASE/ERK KINASE) FOR ERK (EXTRA-CELLULAR SIGNAL REGULATED …

    nus Repository record for BPGAP1 REGULATES MP1 SCAFFOLD FUNCTION IN MEK/ERK SIGNALING (opens in a new tab) Download file for BPGAP1 REGULATES MP1 SCAFFOLD FUNCTION IN MEK/ERK SIGNALING (opens in a new tab)

  4. Exploiting Acquired Resistance Mechanisms To Mek Inhibition In Ras-Activated Neuroblastoma

    … upon relapse that are potentially sensitive to MEK1/2 inhibition with drugs such as trametinib. Although trametinib is a potent MEK1/2 inhibitor, single-agent therapy invariably encounters de novo or acquired bypass mechanisms that allow for disease progression. The central goal of this …

    penn Repository record for Exploiting Acquired Resistance Mechanisms To Mek Inhibition In Ras-Activated Neuroblastoma (opens in a new tab)

  5. Investigating the Anti-Melanoma Activity of Combinatorial Paclitaxel and MEK Inhibitor

    Melanoma has increased considerably over the past forty years. Traditional and newly-developed anti-melanoma drugs do not produce a satisfactory therapeutic response for the treatment of late stage melanoma. Nanomedicine is a potent tool for clinicians to circumvent many of the existing …

    dundee Repository record for Investigating the Anti-Melanoma Activity of Combinatorial Paclitaxel and MEK Inhibitor (opens in a new tab) Download PDF for Investigating the Anti-Melanoma Activity of Combinatorial Paclitaxel and MEK Inhibitor (opens in a new tab)

  6. Die Rolle von NF-kappaB und MEK in der Apoptosesuppression durch Raf

    … proaptotischen Zielgenen. Für den Raf-Effektor MEK ist eine antiapoptotische Funktion bekannt. Hier gelang es mit einer hyperaktiven Mutante (deltaStu-MEK-LIDEMANE) aus IL-3 abhängigen 32D Zellen einen Faktor-unabhängigen Zellpool (FID) zu generieren. Das von den bekannten Vorstellungen über …

    wurz-thes Repository record for Die Rolle von NF-kappaB und MEK in der Apoptosesuppression durch Raf (opens in a new tab)

  7. A Path for Improving Stroke Recovery. Effects of MEK-ERK1/2 Inhibition

    … of mitogen activated protein kinase kinase (MEK)1/2 which is immediately upstream of ERK1/2. In summary, the results of the present thesis showed that acute inhibition of MEKERK1/ 2 pathway is a promising potential treatment for stroke. It has been applicable in a clinically relevant …

    lund Repository record for A Path for Improving Stroke Recovery. Effects of MEK-ERK1/2 Inhibition (opens in a new tab) Download PDF for A Path for Improving Stroke Recovery. Effects of MEK-ERK1/2 Inhibition (opens in a new tab)

  8. A Novel Cytokine Response Modulatory Function of MEK Inhibitors Mediates Therapeutic Efficacy

    … molecules, including EGFR, ALK, BRAF, and MEK. The excitement of immune-checkpoint blockade therapy has triggered concerted efforts that focus on exploring combinations of immune checkpoint therapy with other approved therapeutic regimens aiming at further augmenting positive outcomes and …

    usf Repository record for A Novel Cytokine Response Modulatory Function of MEK Inhibitors Mediates Therapeutic Efficacy (opens in a new tab)

  9. REGULATION OF RHOGAP DLC1 BY FAK, PP2A AND MEK/ERK IN CELL DYNAMICS

    … pathway involving the concerted action of Ras/Mek/Erk pathway, Focal adhesion kinase (FAK) and Protein phosphatase-2A (PP2A) to activate DLC1s GAP function. EGF stimulation not only leads to the phosphorylation of DLC1 but also that of FAK to inactivate it, thus allowing PP2A-mediated …

    nus Repository record for REGULATION OF RHOGAP DLC1 BY FAK, PP2A AND MEK/ERK IN CELL DYNAMICS (opens in a new tab) Download file for REGULATION OF RHOGAP DLC1 BY FAK, PP2A AND MEK/ERK IN CELL DYNAMICS (opens in a new tab)

  10. Development of Dual-Pathway Inhibitors of Raf/MEK/ERK and PI3K/Akt Signaling Pathways.

    … as potential dual-pathway inhibitors of the Raf/MEK/ERK and PI3K/Akt signaling pathways. The design hypothesis is to evaluate whether the oxindole ring system will approximately orient functional groups in a similar manner to the thiazolidinedione moiety, and thus maintain biological activity as …

    vcu Repository record for Development of Dual-Pathway Inhibitors of Raf/MEK/ERK and PI3K/Akt Signaling Pathways. (opens in a new tab)

  11. COMBINATION TREATMENT OF MEK AND CDK4/6 INHIBITORS IN THE AGGRESSIVE PEDIATRIC BRAIN TUMOR ATRT

    … pathway in ATRT. The novel, brain-penetrant MEK inhibitor mirdametinib inhibited the growth of ATRT cell lines in culture at nanomolar concentrations. Mirdametinib suppressed proliferation as measured by BrdU incorporation and induced apoptosis as measured by cPARP and Annexin V staining. …

    jhu Repository record for COMBINATION TREATMENT OF MEK AND CDK4/6 INHIBITORS IN THE AGGRESSIVE PEDIATRIC BRAIN TUMOR ATRT (opens in a new tab) Embargoed until 2029-05-01

  12. Modulation of Antitumor Immunity by the Mek inhibitor Trametinib: Implications for Targeted Therapy of Cancer

    … However, when I focused on the FDA approved MEK inhibitor trametinib, I found that some common γ-chain cytokines were able to rescue T-cell functions blunted by trametinib. Notably, an IL-15 agonist, ALT-803, could rescue the in vivo proliferation of tumor-antigen specific T cells in mice …

    penn Repository record for Modulation of Antitumor Immunity by the Mek inhibitor Trametinib: Implications for Targeted Therapy of Cancer (opens in a new tab)

  13. Design and Synthesis of CDK-5 and MEK-5 Inhibitors and Synthesis towards Tubulysin Analogs

    … of CDK-5 were designed and synthesized. MEK-5, a member of the MAPK family, phosphorylates ERK-5 permitting cells to survive oxidative stress. MEK-5 is upregulated in tumor cells and activated by mitogens; inhibition of this enzyme is a potential anti-cancer strategy. Scaffolds from the …

    duquesne Repository record for Design and Synthesis of CDK-5 and MEK-5 Inhibitors and Synthesis towards Tubulysin Analogs (opens in a new tab)

  14. Μελέτη των σηματοδοτικών οδών BRAF/MEK/ERK και AKT/mTOR στη λευχαιμία εκ τριχωτών κυττάρων

    … or are activated by mTOR and of the integral RAF-MEK-ERK proteins, the interconnection between the two pathways. Of note is that p-4E-BP1 expression, alone or in combination with p-AKT and p-mTOR expression is brought forward as an independent predictor of earlier relapse in HCL.

    greece Repository record for Μελέτη των σηματοδοτικών οδών BRAF/MEK/ERK και AKT/mTOR στη λευχαιμία εκ τριχωτών κυττάρων (opens in a new tab)

Page 1 of 34